Junior Group Leader
Dr. Michael Menden
“Our research focus is studying multi-omics landscapes of complex diseases, understanding their mechanisms, and suggesting novel treatment strategies based on machine learning and biostatistics.”
Translational Computational Pharmacogenomics
The mission of our research group is to develop biostatistical and machine learning frameworks applied to biomedical data, to retrieve insights in the aetiology of complex diseases and identify patient stratifications. For this, we explore deep molecular characterised biomedical datasets, environmental factors, and tailor our models depending on disease-specific knowledge gained through literature and data-driven analyses, thus empowering the next generation of precision medicine.
Career
Dr. Michael P. Menden is a Junior Group Leader at the Computational Health Center, Helmholtz Munich, since 2019. He is leading the Menden Lab and is Head of the DZD Computational Biology Unit. Dr. Menden became an ERC Starting Grant Laureate in 2020 and was awarded the Rising Star in Drug Discovery Award by the University of Cardiff in 2022. Previously, Dr. Menden worked as a Senior Scientist in Oncology Bioinformatics, AstraZeneca, UK. He was a PhD student and postdoctoral fellow at EMBL-EBI, UK. His PhD was awarded in Computational Biology by the University of Cambridge, UK, in 2016. In 2017, Dr. Menden was appointed to an Honorary Lecturer position at the University of Sheffield, UK. Since 2019, Dr. Menden has also become a lecturer at the Technical University of Munich (TUM) and Ludwig Maximilian University (LMU).
Computational Biomedicine
drug discovery Big Data precision medicine drug target identification drug repurposing machine learning biostatistics drug high-throughput screens
Professional Background
Principal Investigator, Computational Biomedicine Group
Institute of Computational Biology (ICB), Helmholtz Munich, Germany
Head of DZD Computational Biology Unit
German Center for Diabetes Research, Helmholtz Munich, Germany
Senior Scientist in Oncology Bioinformatics
Innovative Medicines and Early Development (IMED) Oncology, AstraZeneca, UK
Short-Term Postdoctoral Fellow in Saez-Rodriguez Lab
University Hospital Aachen & RWTH Aachen, Germany
PhD student in Saez-Rodriguez Lab
EMBL-EBI, UK
Visiting Researcher in Sorger Lab
Department of Systems Biology, Harvard Medical School (HMS), USA
Honors and Awards
- 2022 McGuigan Drug Discovery Rising Star Prize, Cardiff University, UK
- 2020 ERC Starting Grant
- 2018 AstraZeneca Award for driving successful external oncology collaborations, UK
- 2017 AstraZeneca Leadership Team Recognition Award, UK
- 2013 Sage Bionetworks Young Investigator Award, Sage Bionetworks, USA
- 2011 EMBL-EBI Pre-Doctoral Fellowship, UK
- 2008 ERASMUS Scholarship, DAAD, Germany
Publications
Scala, E. ; Hillig, C. ; Mercurio, L. ; Fania, L. ; Gubinelli, E. ; Madonna, S. ; Menden, M.P. ; Eyerich, K. ; Eyerich, S. ; Albanesi, C.
331 IL-34 expression and function in hidradenitis suppurativa and psoriasis.Quon, S. ; Johanson, T.M. ; Wadhwa, R. ; Faiz, A. ; Flynn, A. ; Anderson, G.P. ; Cox, A.J. ; West, N.P. ; Menden, M.P. ; Allan, R.S.
Technological advances in the search for a CURE for asthma.Lodge, C. ; Dai, X. ; Laing, I.A. ; Menden, M.P. ; Flynn, A. ; Anderson, G.P. ; Ranganathan, S. ; Dharmage, S.C.
Evidence from Australian cohort studies about asthma trajectories and transitions across the life course: A narrative review.